Advances in glaucoma diagnosis and therapy for the next millennium: New drugs for trabecular and uveoscleral outflow

Seminars in Ophthalmology

Volumn 14, Issue 3, 1999, Pages 130-143

  Kaufman, Paul L ^a   Gabelt, B'Ann ^a   Tian, Baohe ^a   Liu, Xuyang ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ADENOSINE RECEPTOR STIMULATING AGENT; ADRENALIN; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUMETANIDE; CHELATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYTOCHALASIN; CYTOCHALASIN B; DIURETIC AGENT; EDETIC ACID; EGTAZIC ACID; ENDOTHELIN 1; ETACRYNIC ACID; HYALURONIDASE; HYDROLASE; LATANOPROST; LATRUNCULIN; MACROLIDE; MATRIX METALLOPROTEINASE; N ACETYLGALACTOSAMINE 4 SULFATASE; PHENOTHIAZINE DERIVATIVE; PILOCARPINE; PROSTANOID; PROTEIN KINASE INHIBITOR; STAUROSPORINE; TIENILIC ACID; TRANSFORMING GROWTH FACTOR; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNOPROSTONE ISOPROPYL ESTER;

AQUEOUS HUMOR FLOW; CELL ADHESION; CELL INTERACTION; CYTOSKELETON; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE THERAPY; GLAUCOMA; HUMAN; INTRACAMERAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION; TRABECULAR MESHWORK;

EID: 0032874275     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.3109/08820539909061466     Document Type: Review

References (203)

1. Gabelt BT, Kaufman PL. Normal physiology. In: Alm A, Weinreb RN, eds. Uveoscleral Outflow: Biology and Clinical Aspects. London: Mosby-Wolfe Medical Communications; 1998:25-39.
2. Toris CB, Yablonski ME, Camras CB, et al. Uveoscleral outflow decreases with age in ocular normotensive humans. Invest Ophthalmol Vis Sci. 1996;37(ARVO Abstracts):S410.
3. Polansky JR, Bloom E, Konami D, et al. Cultured human trabecular cells: Evaluation of hormonal and pharmacological responses in vitro. In: Ticho U, David R, eds. Recent Advances in Glaucoma. Amsterdam: Excerpta Medica; 1984:201-206.
4. Perkins TW, Alvarado JA, Polansky JR, et al. Trabecular meshwork cells grown on filters: Conductivity and cytochalasin effects. Invest Ophthalmol Vis Sci. 1988;29:1836-1846.
5. Gills JP, Roberts BC, Epstein DL. Microtubule disruption leads to cellular contraction in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1998;39:653-658.
6. Liu X, Glasser A, Croft MA, et al. Effect of H-7 on cultured human trabecular meshwork (HTM) cells. Invest Ophthalmol Vis Sci. 1998;39(ARVO Abstracts):S705.
7. Kaufman PL, Bárány EH. Cytochalasin B reversibly increases outflow facility in the eye of the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 1977;16:47-53.
8. Kaufman PL, Bill A, Bárány EH. Effect of cytochalasin B on conventional drainage of aqueous humor in the cynomolgus monkey. Exp Eye Res 25(Suppl). 1977;411-414.
9. Kaufman PL, Erickson KA. Cytochalasin B and D dose-outflow facility response relationships in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 1982;23:646-650.
10. Kaufman PL. Non-additivity of maximal pilocarpine and cytochalasin effects on outflow facility. Exp Eye Res. 1987;44:283-291.
11. Svedbergh B, Lütjen-Drecoll E, Ober M, et al. Cytochalasin B-induced structural changes in the anterior ocular segment of the cynomolgus monkey. Invest Ophthalmol Vis Sci. 1978;17:718-734.
12. Johnstone M, Tanner D, Chau B, et al. Concentration-dependent morphologic effects of cytochalasin B in the aqueous outflow system. Invest Ophthalmol Vis Sci. 1980;19:835-841.
13. Tian B, Kaufman PL, Volberg T, et al. H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch Ophthalmol. 1998;116:633-643.
14. Peterson JA, Tian B, Bershadsky AD, et al. Latrunculin-A increases outflow facility in the monkey. Invest Ophthalmol Vis Sci. 1999;40:931-941.
15. 2EDTA and EGTA on aqueous outflow routes in the monkey eye. Invest Ophthalmol Vis Sci. 1980;19:492-504.
16. Brenner SL, Korn ED. Substoichiometric concentrations of cytochalasin D inhibit actin polymerization: Additional evidence for an F-actin treadmill. J Biol Chem. 1979;254:9982-9985.
17. Brown SS, Spudich JA. Mechanism of action and cytochalasin: Evidence that it binds to actin filament ends. J Cell Biol. 1981;88:487-491.
18. Davies P, Allison AC. Effects of cytochalasin B on endocytosis and exocytosis. In: Tannenbaum SW, eds. Cytochalasins: Biochemical and Cell Biological Aspects. Amsterdam: North Holland; 1978:143-160.
19. Godman GC, Miranda AF. Cellular contractility and the visible effects of cytochalasin. In: Tannenbaum SW, eds. Cytochalasins: Biochemical and Cell Biological Aspects. Amsterdam: North Holland; 1978;277-429.
20. Cooper JA. Effects of cytochalasins and phalloidin on actin. J Cell Biol. 1987;105:1473-1478.
21. Kolega J, Janson LW, Taylor DL. The role of solation-contraction coupling in regulating stress fiber dynamics in non-muscle cells. J Cell Biol. 1991;114:993-1003.
22. Coué M, Brenner SL, Spector I, et al. Inhibition of actin polymerization by latrunculin A. FEBS Lett. 1987;213:316-318.
23. Spector I, Shochet NR, Blasberger D, et al. Latrunculins-novel marine macrolides that disrupt microfilament organization and affect cell growth: Comparison with cytochalasin D. Cell Motil Cytoskel. 1989;13:27-144.
24. Volberg T, Geiger B, Citi S, et al. Effect of protein kinase inhibitor H-7 on the contractility, integrity, and membrane anchorage of the microfilament system. Cell Motility Cytoskel. 1994;29:321-338.
25. Citi S, Volberg TAD, Bershadsky A, et al. Cytoskeletal involvement in the modulation of cell-cell junctions by the protein kinase inhibitor H-7. J Cell Sci. 1994;107:683-692.
26. Tian B, Millar C, Kaufman PL, et al. Effects of H-7 on the iris and ciliary muscle in monkeys. Arch Ophthalmol. 1998;116:1070-1077.
27. Mobley PL, Hedberg K, Bonin L, et al. Decreased phosphorylation of four 20-kDa proteins precedes staurosporine-induced disruption of the actin/myosin cytoskeleton in rat astrocytes. Exp Cell Res. 1994;214:55-66.
28. Sasaki Y, Seto M, Komatsu K, et al. Staurosporine, a protein kinase inhibitor, attenuates intracellular Ca(2+)-dependent contractions of strips of rabbit aorta. Eur J Pharmacol. 1991;202:367-372.
29. Wiederholt M, Groth J, Strauss O. Role of protein tyrosine kinase on regulation of trabecular meshwork and cilary muscle contractility. Invest Ophthalmol Vis Sci. 1998;39:1012-1020.
30. Farooki AZ, Epstein DL, O'Brien ET. Tyrphostins disrupt stress fibers and cellular attachments in endothelial monolayers. Exp Cell Res. 1998;243:185-198.
31. Gabelt BT, Tian B, Volberg T, et al. Outflow facility effects in monkeys following intracameral (1) H-7 + cytochalasin B; (2) tyrphostins. Invest Ophthalmol Vis Sci. 1998;39(ARVO Abstracts):S483.
32. Sung CP, Arleth AJ, Storer B, et al. Modulation of U937 cell adhesion to vascular endothelial cells by cyclic AMP. Life Sci. 1991;49:375-382.
33. Tripathi BJ, Tripathi RC, Millard CB. Epinephrine-induced toxicity of human trabecular cells in vitro. Lens & Eye Tox Res. 1989;6:141-156.
34. Petty HR, Martin SM. Combinative ligand-receptor interactions: Effects of cAMP, epinephrine, and met-enkephalin on RAW264 macrophage morphology, spreading, adherence, and microfilaments. J Cell Physiol. 1989;138:247-256.
35. FAK in platelets requires coordinated signalling through integrin and agonist receptors. J Biol Chem. 1994;269:14738-14745.
36. 2-Adrenergic stimulation causes detachment of natural killer cells from cultured endothelium. Eur J Immunol. 1993;23:3242-3247.
37. Kawa JE, Higginbotham EJ, Chang IL, et al. Effects of antiglaucoma medications on bovine trabecular meshwork cells in vitro. Exp Eye Res. 1993;57:557-565.
38. Tripathi BJ, Tripathi RC. Effect of epinephrine in vitro on the morphology, phagocytosis, and mitotic activity of human trabecular endothelium. Exp Eye Res. 1984;39:731-744.
39. Alvarado JA. Epinephrine effects on major cell types of the aqueous outflow pathways: In vitro studies/clinical implications. Tr Am Ophth Soc. 1990;88:267-288.
40. Robinson JC, Kaufman PL. Cytochalasin B potentiates epinephrine's outflow facility increasing effect. Invest Ophthalmol Vis Sci. 1991;32:1614-1618.
41. Robinson JC, Kaufman PL. Phalloidin inhibits epinephrine's and cytochalsin B's facilitation of aqueous outflow. Arch Ophthalmol. 1994;112:1610-1613.
42. Croft MA, Kaufman PL. Effect of daily topical ethacrynic acid on aqueous humor dynamics in monkeys. Curr Eye Res. 1995;14:777-781.
43. Croft MA, Hubbard WC, Kaufman PL. Effect of ethacrynic acid on aqueous outflow dynamics in monkeys. Invest Ophthalmol Vis Sci. 1994;35:1167-1175.
44. Epstein DL, Freddo TF, Bassett-Chu S, et al. Influence of ethacrynic acid on outflow facility in the monkey and calf eye. Invest Ophthalmol Vis Sci. 1987;28:2067-2075.
45. Johnson DH, Tschumper RC. Ethacrynic acid: Outflow effects and toxicity in human trabecular meshwork in perfusion organ culture. Curr Eye Res. 1993;12:385-396.
46. Liang L-L, Epstein DL, de Kater AW, et al. Ethacrynic acid increases facility of outflow in the human eye in vitro. Arch Ophthalmol. 1992;110:106-109.
47. Matthews JB, Awtrey CS, Madara JL. Microfilament-dependent activation of Na/K/2Cl cotransport by cAMP in intestinal epithelial monolayers. J Clin Invest. 1992;90:1608-1613.
48. Jessen F, Hoffmann EK. Activation of the Na/K/Cl cotransport system by reorganization of the actin filaments in Ehrlich ascites tumor cells. Biochim Biophys Acta. 1992; 1110:199-201.
49. O'Donnell ME. Role of Na-K-Cl cotransport in vascular endothelial cell volume regulation. Am J Physiol. 1993;264: C1316-C1326.
50. O'Donnell ME, Brandt JD, Curry F-RE. Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995;268: C1067-C1074.
51. Putney LK, Brandt JD, O'Donnell ME. Effects of dexamethasone on sodium-potassium-chloride cotransport in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1997;38: 1229-1240.
52. Gabelt BT, Wiederholt M, Clark AF, et al. Anterior segment physiology following bumetanide inhibition of Na-K-Cl cotransport. Invest Ophthalmol Vis Sci. 1997;38:1700-1707.
53. Wiederholt M, Dörschner N, Groth J. Effect of diuretics, channel modulators, and signal interceptors on contractility of the trabecular meshwork. Ophthalmologica. 1997;211:153-160.
54. Putney LK, Brandt JD, O'Donnell ME. Na-K-Cl cotransport in normal and glaucomatous human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1999;40:425-434.
55. Kaufman PL. Pharmacologic trabeculocanalotomy. Facilitating aqueous outflow by assaulting the meshwork cytoskeleton, junctional complexes, and extracellular matrix. Arch Ophthalmol. 1992;110:34-36.
56. Epstein DL. Open angle glaucoma. Why not a cure? [editorial]. Arch Ophthalmol. 1987;105:1187-1188.
57. Inomata H, Bill A, Smelser GK. Aqueous humor pathways through the trabecular meshwork and into Schlemm's canal in the cynomolgus monkey (Macaca irus). Am J Ophthalmol. 1972;73:760-789.
58. Bill A, Svedbergh B. Scanning electron microscopic studies of the trabecular meshwork and the canal of Schlemm: An attempt to localize the main resistance to outflow of aqueous humor in man. Acta Ophthalmol. 1972;50:295-320.
59. Bill A. Blood circulation and fluid dynamics in the eye. Physiol Rev. 1975;55:383-417.
60. Bárány EH, Scotchbrook S. Influence of testicular hyaluronidase on the resistance to flow through the angle of the anterior chamber. Acta Physiol Scand. 1954;30:240-248.
61. Pedler WS. The relationship of hyaluronidase to aqueous outflow resistance. Trans Ophthalmol Soc UK. 1956;76:51-63.
62. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1963;69:783-801.
63. Peterson WS, Jocson VL. Hyaluronidase effects on aqueous outflow resistance: Quantitative and localizing studies in the rhesus monkey eye. Am J Ophthalmol. 1974;77:573-577.
64. Hubbard WC, Johnson M, Gong H, et al. Intraocular pressure and outflow facility are unchanged following acute and chronic intracameral chondroitinase ABC and hyaluronidase in monkeys. Exp Eye Res. 1997;65:177-190.
65. 2EDTA and alpha-chymotrypsin on aqueous humor outflow conductance in monkey eyes. Uppsala J Med Sci. 1980;85:311-319.
66. Sawaguchi S, Yue BY, Yeh P, et al. Effects of intracameral injection of chondroitinase ABC in vivo. Arch Ophthalmol. 1992;110:110-117.
67. Hanamaka T, Bill A. Effect of α-chymotrypsin on the outflow routes for aqueous humor. Exp Eye Res. 1988; 46:323-341.
68. Cousins SW, McCabe MM, Danielpour D, et al. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;32:2201-2211.
69. Streilein JW, Bradley D. Analysis of immunosuppressive properties of iris and ciliary body cells and their secretory products. Invest Ophthalmol Vis Sci. 1991;32:2700-2710.
70. Streilein JW, Wilbanks GA, Cousins SW. Immunoregulatory mechanisms of the eye. J Neuroimmunol. 1992;39:185-200.
71. Streilein JW, Wilbanks GA, Taylor A, et al. Eye-derived cytokines and the immunosuppressive intraocular microenvironment: A review. Curr Eye Res. 1992;11(Suppl):41-47.
72. Tripathi RC, Borisuth NS, Kolli SP, et al. Trabecular cells express receptors that bind TGF-beta 1 and TGF-beta 2: A qualitative and quantitative characterization. Invest Ophthalmol Vis Sci. 1993;34:260-263.
73. Borisuth NS, Tripathi BJ, Tripathi RC. Identification and partial characterization of TGF-beta 1 receptors on trabecular cells. Invest Ophthalmol Vis Sci. 1992;33:596-603.
74. Tripathi RC, Li J, Borisuth NS, et al. Trabecular cells of the eye express messenger RNA for transforming growth factor-beta 1 and secrete this cytokine. Invest Ophthalmol Vis Sci. 1993;34:2562-2569.
75. Tripathi RC, Chan WF, Li J, et al. Trabecular cells express the TGF-beta 2 gene and secrete the cytokine. Exp Eye Res. 1994;58:523-528.
76. Lütjen-Drecoll E, Liebe S, Prehm P. HA-receptors and regulation of HA-synthesis in the primate trabecular meshwork. Invest Ophthalmol Vis Sci. 1995;36(ARVO Abstracts):S725.
77. Siegner A, Lütjen-Drecoll E. Transforming growth factor-β1 stimulates human trabecular meshwork cells to produce increased amounts of collagen type VI mRNA. Invest Ophthalmol Vis Sci. 1995;36(ARVO Abstract):S727.
78. Alexander JP, Samples JR, Acott TS. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res. 1998;17:276-285.
79. Seong GJ, Kay EP, Minckler DS. Regulation of the levels of trabecular matrix metalloproteinases by transforming growth factor β1. Invest Ophthalmol Vis Sci. 1995;36(ARVO Abstracts):S727.
80. Clark AF. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci. 1998;39:2514-2516.
81. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32: 172-180.
82. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993;34:3386-3395.
83. Bradley JMB, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
84. Parshley DE, Bradley JM, Samples JR, et al. Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr Eye Res. 1995;14:537-544.
85. Parshley DE, Bradley JM, Fisk A, et al. Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells. Invest Ophthalmol Vis Sci. 1996;37:795-804.
86. Lütjen-Drecoll E, Rohen JW. Morphology of aqueous outflow pathways in normal and glaucomatous eyes. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis, MO: Mosby; 1996:89-123.
87. Hernandez MR, Gong H. Extracellular matrix of the trabecular meshwork and optic nerve head. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas, Basic Sciences, 2nd edition. St. Louis, MO: Mosby; 1996:213-249.
88. Geiger B, Tokuyasu KT, Dutton AH, et al. Vinculin, an intracellular protein localized at specialized sites where microfilament bundles terminate at cell membranes. Proc Natl Acad Sci USA. 1980;77:4127-4131.
89. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J. 1989;8:1711-1717.
90. Geiger B, Yehuda-Levenberg S, Bershadsky AD. Molecular interactions in the submembrane plaque of cell-cell and cell-matrix adhesions. Acta Anat. 1995;154:46-62.
91. Yamada KM, Geiger B. Molecular interactions in cell adhesion complexes. Curr Opin Cell Biol. 1997;9:75-85.
92. Ben-Ze'ev A, Rodriguez Fernandez JL, Gluck U, et al. Changes in adhesion plaque protein levels regulate cell motility and tumorigenicity. Adv Exp Med Biol. 1994;358:147-157.
93. Sampath P, Pollard TD. Effects of cytochalasin, phalloidin, and pH on the elongation of actin filaments. Biochem. 1991;30:1973-1980.
94. Birrell GB, Hedberg KK, Habliston DL, et al. Protein kinase C inhibitor H-7 alters the actin cytoskeleton of cultured cells. J Cell Physiol. 1989;141:74-84.
95. Tian B, Gabelt BT, Kaufman PL. Effect of staurosporine on outflow facility in monkeys. Invest Ophthalmol Vis Sci. 1999;40:1009-1011.
96. Tian B, Gabelt BT, Peterson JA, et al. H-7 increases trabecular facility and facility after ciliary muscle disinsertion in monkeys. Invest Ophthalmol Vis Sci. 1999;40:239-242.
97. Kaufman PL, Peterson JA, Tian B, et al. An actin drug for glaucoma? Exp Eye Res. 1998;67(Suppl 1, XIII ICER Abstracts):S53.
98. Gabelt BT, Sabanai I, Tian B, et al. Effect of the protein kinase inhibitor H-7 on the structure and fluid conductance of the trabecular meshwork of live monkeys. Invest Ophthalmol Vis Sci. 1999;40(ARVO Abstracts):S667.
99. Gabelt BT, Kaufman PL. Pharmacologic enhancement of aqueous humor outflow. In: Van Buskirk Em, Shields MB, eds. 100 Years of Progress in Glaucoma. Philadelphia, PA: Lippincott; 1997:237-261.
100. Rohen JW, Lütjen E, Bárány E. The relation between the ciliary muscle and the trabecular meshwork and its importance for the effect of miotics on aqueous outflow resistance. Graefes Arch Clin Exp Ophthalmol. 1967;172:23-47.
101. Kaufman PL. Total iridectomy does not alter outflow facility responses to cyclic AMP in cynomolgus monkeys. Exp Eye Res. 1986;43:441-447.
102. Kaufman PL, Bárány EH. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest Ophthalmol. 1976;15:793-807.
103. Kaufman PL, Gabelt BT. Direct, indirect and dual action parasympathetic drugs. In: Zimmerman TJ, ed. Textbook of Ocular Pharmacology. Philadelphia, PA: Lippincott; 1997:221-238.
104. Gupta N, Drance SM, McAllister R, et al. Localization of M3 muscarinic receptor subtype and mRNA in the human eye. Ophthalmic Res. 1994;26:207-213.
105. Gupta N, McAllister R, Drance SM, et al. Muscarinic receptor M1 and M2 subtypes in the human eye: QNB, pirenzipine, oxotremorine, and AFDX-116 in vitro autoradiography. Br J Ophthalmol. 1994;78:555-559.
106. Zhang X, Hernandez MR, Yang H, et al. Expression of muscarinic receptor subtype mRNA in the human ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36:1645-1657.
107. Ishikawa H, DeSantis L, Patil PN. Selectivity of muscarinic agonists including (±)-aceclidine and antimuscarinics on the human intraocular muscles. J Ocular Pharmacol Ther. 1998;14:363-373.
108. Gil DW, Krauss HA, Bogardus AM, et al. Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest Ophthalmol Vis Sci. 1997;38:1434-1442.
109. WoldeMussie E, Feldmann B, Chen J. Characterization of muscarinic receptors in cultured human iris sphincter and ciliary smooth muscle cells. Exp Eye Res. 1993;56:385-392.
110. Wiederholt M, Schafer R, Wagner U, et al. Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. German J Ophthalmol. 1996;5:146-153.
111. Flügel C, Bárány EH, Lütjen-Drecoll E. Histochemical differences within the ciliary muscle and its function in accommodation. Exp Eye Res. 1990;50:219-226.
112. Erickson-Lamy KA, Kaufman PL. Effect of cholinergic drugs on outflow facility after ciliary ganglionectomy. Invest Ophthalmol Vis Sci. 1988;29:491-494.
113. Erickson-Lamy KA, Kaufman PL, Polansky JR. Dissociation of cholinergic supersensitvity from receptor number in ciliary muscle. Invest Ophthalmol Vis Sci. 1988;29:600-605.
114. Erickson-Lamy KA, Kaufman PL. Reinnervation of primate ciliary muscle following ciliary ganglionectomy. Invest Ophthalmol Vis Sci. 1987;28:927-933.
115. Kaufman PL, Erickson-Lamy KA, Rohen JW, et al. The ciliary muscle and nerves after ciliary ganglionectomy. In: Krieglstein GK, ed. Glaucoma Update IV. Proceedings of the Symposium of the Glaucoma Society of the International Congress of Ophthalmology in Bali. Berlin: Springer-Verlag; 1991:36-51.
116. Bárány EH. Dissociation of accommodation effects from outflow effects of pilocarpine. In: Paterson G, Miller SJH, Paterson GH, eds. Drug Mechanisms in Glaucoma. London: Churchill Ltd; 1966;275-282.
117. Croft MA, Oyen MJ, Gange SJ, et al. Aging effects on accommodation and outflow facility responses to pilocarpine in humans. Arch Ophthalmol. 1996;114:586-592.
118. Erickson-Lamy K, Schroeder A. Dissociation between the effect of aceclidine on outflow facility and accommodation. Exp Eye Res. 1990;50:143-147.
119. Gabelt BT, Kaufman PL. Inhibition of aceclidine-stimulated outflow facility, accommodation, and miosis by muscarinic receptor subtype antagonists in rhesus monkeys. Exp. Eye Res. 1994;58:623-630.
120. Lieberman TW, Leopold IH. The use of aceclidine in the treatment of glaucoma. Its effect on intraocular pressure and facility of aqueous humor outflow as compared to that of pilocarpine. Am J Ophthalmol. 1967;64:405-415.
121. Romano JH. Double-blind crossover comparison of aceclidine and pilocarpine in open-angle glaucoma. Br J Ophthalmol. 1970;54:510-521.
122. Gabelt BT, Kaufman PL. Inhibition of outflow facility, accommodative, and miotic responses to pilocarpine in rhesus monkeys by muscarinic receptor subtype antagonists. J Pharmacol Exp Ther. 1992;263:1133-1139.
123. Poyer JF, Gabelt BT, Kaufman PL. The effect of muscarinic agonists and selective receptor subtype antagonists on the contractile response of the isolated rhesus monkeys ciliary muscle. Exp Eye Res. 1994;59:729-736.
124. Erickson-Lamy K, Korbmacher C, Schuman JS, et al. Effect of endothelin on outflow facility and accommodation in the monkey eye in vivo. Invest Ophthalmol Vis Sci. 1991;32:492-495.
125. Millar JC, Gabelt BT, Hubbard WC, et al. Endothelin-1 effects on aqueous humor dynamics in monkeys. Acta Opthalmol. 1998;76:663-667.
126. Millar C, Poyer JF, Gabelt BT, et al. Endothelin subtypes: Effect on isolated rhesus monkey ciliary muscle. J Pharmacol Exp Ther. 1995;275:1143-1147.
127. Nardin GF, Zimmerman TJ. Ocular cholinergic agents. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis, MO: Mosby; 1996:1399-1407.
128. 2α receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:315-321.
129. Woodward DF, Regan JW, Lake S, et al. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol. 1997;41(Suppl 2):S15-S21.
130. Toris CB, Camras CB, Yablonski ME, et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood aqueous barrier function. Surv Ophthalmol. 1997; 41(Suppl 2):S69-S75.
131. 2α in the organ culture anterior segment perfusion model in human eyes. Invest Ophthalmol Vis Sci. 1995;36(ARVO Abstracts):S137.
132. 2 on outflow facility in the human eye. Invest Ophthalmol Vis Sci. 1994;35(ARVO Abstracts):S2053.
133. 2 on aqueous humor dynamics in monkeys. Arch Ophthalmol. 1998;116:1213-1216.
134. Kamikawatoko S, Tokoro T, Azuma H, et al. The effects of endothelin-1 on isolated bovine ciliary muscles. Exp Eye Res. 1995;61:559-564.
135. Lepple-Wienhues A, Stahl F, Wunderling D, et al. Effects of endothelin and calcium channel blockers on membrane voltage and intracellular calcium in cultured bovine trabecular meshwork cells. Ger J Ophthalmol. 1992;1:159-163.
136. Crosson CE. Ocular hypotensive activity of the adenosine agonist (R)-phenylisopropyladenosine in rabbits. Curr Eye Res. 1992;11:453-458.
137. Tian B, Gabelt BT, Crosson CE, et al. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res. 1997;64:979-989.
138. Crosson CE, Gray T. Adenosine agonists alter aqueous flow and outflow facility in rabbits. Invest Ophthalmol Vis Sci. 1997;38(ARVO Abstracts):S821.
139. Crosson CE. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther. 1995;273:320-326.
140. Crosson CE, Gray T. Modulation of intraocular pressure by adenosine agonists. J Ocular Pharmacol. 1994;10:379-383.
141. Croft MA, Kiland J, Peterson J, et al. Effects of promazine hydrochloride on aqueous humor dynamics in monkeys. Invest Ophthalmol Vis Sci. 1995;36(ARVO Abstract):S734.
142. Croft MA, Kaufman PL. Effect of acepromazine maleate (Promace) on aqueous humor dynamics. Invest Ophthalmol Vis Sci. 1994;35(ARVO Abstract):2051.
143. Hayreh SS, Kardon RH, McAllister DL, et al. Acepromazine. Effects on intraocular pressure. Arch Ophthalmol. 1991;109:119-124.
144. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389-402.
145. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707-716.
146. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha, on aqueous humor dynamics in human eyes. Ophthalmol. 1993;100:1297-1304.
147. 2α on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res. 1990;51:87-91.
148. Stjernschantz J, Selen G, Sjöquist B, et al. Preclinical pharmacology of latanoprost, a phenylsubstituted PGF2a analogue. In: Samuelsson B, ed. Advances in Prostaglandin, Thromboxance, and Leukotriene Research. New York, NY: Raven Press; 1995;513-518.
149. 2α effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36:2461-2465.
150. van Alphen GWHM, Kern R, Robinette SL. Adrenergic receptors of the intraocular muscles. Comparison to cat, rabbit, and monkey. Arch Ophthalmol. 1965;74:253-259.
151. van Alphen GWHM, Robinette SL, Macri FJ. Drug effects on ciliary muscle and choroid preparations in vitro. Arch Ophthalmol. 1962;68:111-123.
152. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism - implications for uveoscleral outflow. Surv Ophthalmol. 1997;41:S53-S59:(Suppl 2).
153. 2α. Exp Eye Res. 1988;47:761-769.
154. 2α. Fortschr Ophthalmol. 1990;87:623-629.
155. 2α alters extracellular matrix collagens in ciliary muscle, iris root and sclera of monkey eyes in vivo. Invest Ophthalmol Vis Sci. 1998;39(ARVO Abstracts):S803.
156. Lindsey JD, Weinreb RN. Effects of prostaglandins on uveoscleral outflow. In: Alm A, Weinreb RN, eds. Uveoscleral Outflow: Biology and Clinical Aspects. Barcelona: Mosby-Wolfe Medical Communications; 1998;41-55.
157. 2α in iris root, ciliary muscle, and adjacent sclera of monkey eyes. Invest Ophthalmol Vis Sci. 1998;39(ARVO Abstracts):S929.
158. Sagara T, Gaton DD, Lindsey JD, et al. Collagen type I is reduced in the ciliary muscle of inflamed monkey eyes. Invest Ophthalmol Vis Sci. 1998 (in press).
159. Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci. 1987;28:477-481.
160. Weinreb RN, Mitchell MD, Alvarado JA, et al. Glucocorticoid regulation of eicosandoid biosynthesis in cultured human trabecular cells. In: Ticho U, David R, eds. Recent Advances in Glaucoma. Amsterdam: Elsevier Sciences Publishers BV; 1984:213-218.
161. Matsumoto S, Yorio T, Magnino PE, et al. Endothelin-induced changes of second messengers in cultured human ciliary muscle cells. Invest Ophthalmol Vis Sci. 1996;37:1058-1066.
162. Kaufman PL, Mittag TW. Medical therapy of glaucoma. In: Kaufman PL, Mittag TW, eds. Glaucoma. London: Mosby-Year Book Europe Ltd; 1994:9.7-9.30.
163. McGetrick JJ, Wilson DG, Dortzbach RK, et al. A search for lymphatic drainage of the monkey orbit. Arch Ophthalmol. 1989;107:255-260.
164. Camras CB, Alm A, Watson PG, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy: Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmol. 1996;103:1916-1924.
165. Azuma I, Masuda K, Kitazawa Y, et al. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jap J Ophthalmol. 1993;37:514-525.
166. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
167. Sakuai M, Araie M, Oshika T, et al. Effects of topical application of F-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1991;35:156-165.
168. Serle JB, Podos SM, Kitazawa Y, et al. A camparative study of latanoprost (Xalatan) and isopropyl unoporostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol. 1998;42:95-100.
169. Linden C, Alm A. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch Ophthalmol. 1997;115:857-861.
170. 2α-induced ocular hypotension: Evidence for enhancement of uveoscleral outflow by PGF2α. Arch Ophthalmol. 1987;105:1112-1116.
171. Kaufman PL. Prostaglandins and cholinomimetics (editorial). Arch Ophthalmol. 1997;115:911-913.
172. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517.
173. Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456-461.
174. Toris CB, Camras CB, Yablonski ME, et al. Acute versus chronic effects of brimonidine on aqueous humor dynamics in human eyes. Invest Ophthalmol Vis Sci. 1997;38(ARVO Abstracts):S243.
175. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999;117:586-591.
176. Wang RF, Camras CB, Podos SM, et al. The role of prostaglandins in the para-aminoclonidine-induced reduction of intraocular pressure. Trans Am Ophthalmol Soc. 1989;87:94-104.
177. Lee P-Y, Serle JB, Podos SM, et al. Time course of the effect of UK 14304-18 (brimonidine tartrate) on rabbit uveoscleral outflow. Invest Ophthalmol Vis Sci. 1992;33(ARVO Abstracts):1118.
178. Bito LZ. Species differences in the response of the eye to irritation and trauma: A hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research. Exp Eye Res. 1984;39:807-829.
179. 2α on uveoscleral outflow and outflow facility in the rabbit eye. Exp Eye Res. 1992;54:277-283.
180. Lin P-J, Hung P-T, Wang T-H, Ho T-C. Effect of topical indomethacin and apraclonidine hydrochloride on intraocular pressure in normal subjects. Invest Ophthalmol Vis Sci 1991;32:988(suppl).
181. McCannel C, Koskela T, Brubaker RF. Topical flurbiprofen pretreatment does not block apraclonidine's effect on aqueous flow in humans. Arch Ophthalmol. 1991;109:810-811.
182. Siegel MJ, Camras CB, Lustgarten JS, et al. Effect of flurbiprofen on the reduction of intraocular pressure after administration of 1% aproclonidine in patients with glaucoma (letter to editor). Arch. Ophthalmol. 1992:110:598-599.
183. Sulewski M, Robin AL, Cummings HL, et al. Effects of topical flurbiprofen on the intraocular pressure lowering effects of apraclonidine and timolol. Arch Ophthalmol. 1991;109:807-809.
184. Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456-461.
185. α2-Adrenergic agonist effects on aqueous humor dynamics. J Glaucoma. 1995;4:S8-S14(suppl 1).
186. Ritch R, Shields MB, Krupin T. Chronic open-angle glaucoma: Treatment overview. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas, 2nd edition. St. Louis, MO: Mosby Year-Book, Inc; 1996:1507-1519.
187. 2α or epinephrine on cynomolgus monkey eyes.
188. Johnson DH. Cytochalasin D increases outflow facility in the human eye in perfusion organ culture. Invest Ophthalmol Vis Sci. 1996;37(ARVO Abstracts):S894.
189. Tian B, Gabelt BT, Hubbard WC, et al. Effects of protein kinase inhibitors on trabecular and total outflow facility in monkeys. Invest Ophthalmol Vis Sci. 1997;38(ARVO Abstracts): S812.
190. Peterson JA, Tian B, Kiland JA, et al. Latrunculin (LAT-A) & staurosporin, but not swinholide (SWIN)-A, increase outflow facility in the monkey. Invest Ophthalmol Vis Sci. 1996;37(ARVO Abstract):S825.
191. Peterson JA, Tian B, Geiger B, et al. In cynomolgus monkeys latrunculin (LAT)-A, LAT-B increase outflow facility, LAT-A decreases intraocular pressure and initially increases aqueous humor formation. Invest Ophthalmol Vis Sci. 1997; 38(ARVO Abstracts):S243.
192. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J. 1989;259:315-324.
193. Ryder MI, Weinreb RN, Alvarado J, et al. The cytoskeleton of the cultured human trabecular cell. Invest Ophthalmol Vis Sci. 1988;29:251-260.
194. Theriot JA. Regulation of the actin cytoskeleton in living cells. Cell Biol. 1994;5:193-199.
195. Gips SJ. Growth factor receptors, phospholipases, phospholipid kinases, and actin reorganization. Cell Biol. 1994;5:201-208.
196. Liu X, Brandt CR, Gabelt BT, et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res. 1999 (in press).
197. Borrás T, Tamm E, Zigler Jr JS. Ocular adenovirus gene transfer varies in efficiency and inflammatory response. Invest Ophthalmol Vis Sci. 1996;37:1282-1293.
198. Borrás T, Masumoto Y, Epstein DL, et al. Gene transfer to the human trabecular meshwork by anterior segment perfusion. Invest Ophthalmol Vis Sci. 1998;39:1503-1507.
199. Kaufman PL, Jia WW-G, Tan J, et al. A perspective of gene therapy in the glaucomas. Surv Ophthalmol. 1999; 43:S91-S97.
200. Skinner LL, Borrás T, Epstein DL. Effect of replication deficient adenovirus vectors on outflow facility of excised pig eyes. Invest Ophthalmol Vis Sci. 1997;38(ARVO Abstracts):S565.
201. Borrás T, Rowlette LLS, Epstein DL. Adenovirus vector concentration affects the outflow facility of human perfused organ cultures. Invest Ophthalmol Vis Sci. 1998;39(ARVO Abstracts):S235.
202. Kaufman PL, Gabelt BT, Cynader M. Introductory comments on neuroprotection. Surv Ophthalmol. 1999(in press).
203. Yang NS. Gene transfer into mammalian somatic cells in vivo. Crit Rev Biotech. 1992;12:335-356.